Mark Kirschbaum

8.6k total citations · 3 hit papers
66 papers, 6.2k citations indexed

About

Mark Kirschbaum is a scholar working on Molecular Biology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Mark Kirschbaum has authored 66 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 31 papers in Hematology and 25 papers in Pathology and Forensic Medicine. Recurrent topics in Mark Kirschbaum's work include Histone Deacetylase Inhibitors Research (29 papers), Lymphoma Diagnosis and Treatment (24 papers) and Acute Myeloid Leukemia Research (23 papers). Mark Kirschbaum is often cited by papers focused on Histone Deacetylase Inhibitors Research (29 papers), Lymphoma Diagnosis and Treatment (24 papers) and Acute Myeloid Leukemia Research (23 papers). Mark Kirschbaum collaborates with scholars based in United States, Australia and Israel. Mark Kirschbaum's co-authors include Arnon Nagler, Simcha Samuel, Avraham Amar, Gàbor Varadi, Reuven Or, Shimon Slavin, Memet Aker, E Naparstek, A Eldor and Gabriel Cividalli and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Mark Kirschbaum

65 papers receiving 6.0k citations

Hit Papers

Nonmyeloablative Stem Cell Transplantation and Cell Thera... 1998 2026 2007 2016 1998 1998 2009 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
    1998 1.6k citations Shimon Slavin, Arnon Nagler et al. Blood profile →
  2. Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
    1998 1.5k citations Shimon Slavin, Arnon Nagler et al. Blood profile →
  3. Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
    2009 561 citations Richard Piekarz, Robin Frye et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Kirschbaum United States 25 3.2k 2.1k 1.9k 1.7k 1.1k 66 6.2k
David A. Rizzieri United States 44 4.3k 1.4× 2.5k 1.2× 3.0k 1.6× 1.6k 0.9× 916 0.8× 309 8.1k
Anthony S. Stein United States 43 3.9k 1.2× 2.9k 1.4× 1.5k 0.8× 1.2k 0.7× 873 0.8× 242 6.8k
Keith Stockerl‐Goldstein United States 36 3.3k 1.0× 1.8k 0.9× 1.7k 0.9× 1.4k 0.8× 588 0.5× 200 5.2k
Corrado Tarella Italy 41 2.5k 0.8× 2.8k 1.4× 1.0k 0.6× 1.3k 0.7× 2.8k 2.4× 213 6.2k
Martin Gramatzki Germany 46 1.8k 0.6× 2.5k 1.2× 2.1k 1.1× 2.6k 1.6× 1.2k 1.0× 207 6.8k
Thierry Lamy France 41 1.9k 0.6× 2.3k 1.1× 1.4k 0.7× 2.6k 1.5× 2.6k 2.2× 177 6.4k
C. Cameron Yin United States 37 1.7k 0.5× 1.4k 0.7× 950 0.5× 841 0.5× 1.7k 1.5× 226 4.6k
Michinori Ogura Japan 43 1.5k 0.5× 3.0k 1.4× 1.2k 0.7× 2.2k 1.3× 3.2k 2.8× 223 7.3k
Dina Ben‐Yehuda Israel 35 1.7k 0.5× 1.3k 0.6× 2.1k 1.1× 579 0.3× 1.4k 1.2× 124 4.8k
Craig B. Reeder United States 34 2.5k 0.8× 2.3k 1.1× 2.7k 1.4× 628 0.4× 2.3k 2.0× 142 5.8k

Countries citing papers authored by Mark Kirschbaum

Since Specialization
Citations

This map shows the geographic impact of Mark Kirschbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Kirschbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Kirschbaum more than expected).

Fields of papers citing papers by Mark Kirschbaum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Kirschbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Kirschbaum. The network helps show where Mark Kirschbaum may publish in the future.

Co-authorship network of co-authors of Mark Kirschbaum

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Kirschbaum. A scholar is included among the top collaborators of Mark Kirschbaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Kirschbaum. Mark Kirschbaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tuscano, Joseph M., Emanual Maverakis, Susan Groshen, et al.. (2019). A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma. Clinical Cancer Research. 25(23). 7004–7013. 34 indexed citations
2.
3.
Chen, Robert, Paul Frankel, Leslie Popplewell, et al.. (2015). A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica. 100(3). 357–362. 61 indexed citations
4.
Kirschbaum, Mark, Ivana Gojo, Stuart L. Goldberg, et al.. (2014). A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. British Journal of Haematology. 167(2). 185–193. 96 indexed citations
5.
6.
Jain, Nitin, Emily Curran, Neil M. Iyengar, et al.. (2012). Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML).. Journal of Clinical Oncology. 30(15_suppl). 6582–6582. 6 indexed citations
7.
Kretzner, Leo, Anna Scuto, Claudia Kowolik, et al.. (2011). Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels. Cancer Research. 71(11). 3912–3920. 89 indexed citations
8.
Kirschbaum, Mark, Timothy W. Synold, Anthony S. Stein, et al.. (2011). A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia. Leukemia. 25(10). 1543–1547. 14 indexed citations
9.
Kirschbaum, Mark, Bryan Goldman, Jasmine Zain, et al.. (2011). A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leukemia & lymphoma. 53(2). 259–262. 59 indexed citations
10.
Kirschbaum, Mark, Anthony S. Stein, Leslie Popplewell, et al.. (2011). A Phase I Study in Adults of Clofarabine Combined with High-Dose Melphalan as Reduced-Intensity Conditioning for Allogeneic Transplantation. Biology of Blood and Marrow Transplantation. 18(3). 432–440. 19 indexed citations
11.
Piekarz, Richard, Robin Frye, H. Miles Prince, et al.. (2011). Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 117(22). 5827–5834. 359 indexed citations
12.
Piekarz, Richard, Erin R. Gardner, Zhirong Zhan, et al.. (2008). Pharmacokinetic and biomarker analysis in a phase II trial of the HDAC inhibitor romidepsin, FK228. Cancer Research. 68. 5831–5831. 1 indexed citations
13.
Jiang, Chunling, Bingsen Zhou, Kenneth L. Fan, et al.. (2008). A sequential treatment of depsipeptide followed by 5-azacytidine enhances Gadd45beta expression in hepatocellular carcinoma cells.. PubMed. 27(6B). 3783–9. 15 indexed citations
14.
Kirschbaum, Mark. (2008). hENT1 and Hodgkin lymphoma: Not just crossing the channel. Leukemia & lymphoma. 49(6). 1024–1025. 1 indexed citations
15.
Scuto, Anna, Mark Kirschbaum, Claudia Kowolik, et al.. (2008). The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph− acute lymphoblastic leukemia cells. Blood. 111(10). 5093–5100. 119 indexed citations
16.
Kirschbaum, Mark, Leslie Popplewell, Auayporn Nademanee, et al.. (2008). A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma. A California Cancer Consortium Study.. Blood. 112(11). 1564–1564. 7 indexed citations
17.
18.
Klapper, Leah N., et al.. (1999). Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors. Advances in cancer research. 77. 25–79. 460 indexed citations
19.
Varadi, Gàbor, Reuven Or, Joseph Kapelushnik, et al.. (1999). Graft-Versus-Lymphoma Effect after Allogeneic Peripheral Blood Stem Cell Transplantation for Primary Central Nervous System Lymphoma. Leukemia & lymphoma. 34(1-2). 185–190. 36 indexed citations
20.
Sharon, Elad, et al.. (1998). Chronic graft-versus-host disease treated with UVB phototherapy. Bone Marrow Transplantation. 22(12). 1179–1183. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David A. Rizzieri Breakdown of academic impact, for papers by Anthony S. Stein Breakdown of academic impact, for papers by Keith Stockerl‐Goldstein Breakdown of academic impact, for papers by Corrado Tarella Breakdown of academic impact, for papers by Martin Gramatzki Breakdown of academic impact, for papers by Thierry Lamy Breakdown of academic impact, for papers by C. Cameron Yin Breakdown of academic impact, for papers by Michinori Ogura Breakdown of academic impact, for papers by Dina Ben‐Yehuda Breakdown of academic impact, for papers by Craig B. Reeder
Rankless by CCL
2026